Greenyn Biotechnology , Ltd Overview
Get informed when a big investor buys or sells
+ Follow12.30
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
Greenyn Biotechnology , Ltd (6846.TWO) currently reports a P/E ratio of 12.3. That is below the Healthcare sector average of 70.94. Use the charts on this page to explore Greenyn Biotechnology , Ltd's P/E ratio history and peer comparisons.
Greenyn Biotechnology , Ltd's P/E ratio of 12.3 is lower than the Healthcare sector average of 70.94. That is roughly 82.7% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
The P/E ratio is a valuation multiple that relates Greenyn Biotechnology , Ltd's market price to a fundamental measure such as earnings, sales, or book value. At 12.3, 6846.TWO can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.
Start with the current P/E ratio of 12.3, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 70.94. From there, open related valuation or income-statement pages for Greenyn Biotechnology , Ltd, and consider following 6846.TWO for alerts when major investors trade the stock.
Greenyn Biotechnology , Ltd is classified in the Healthcare sector. On P/E ratio, it currently shows 12.3 versus a sector average near 70.94. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing 6846.TWO with unrelated industries.
